Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

A technology of doxorubicin and liposomes, which can be used in liposome delivery, pharmaceutical formulations, medical preparations containing active ingredients, etc., and can solve problems such as toxicity and no overall survival rate.

Inactive Publication Date: 2008-04-16
ALZA CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, randomized trials have not shown good results in overall survival of patients treated with prolonged chemotherapy, and additional cycles of chemotherapy can lead to severe toxicity (Hakes, T.B., et al., Gynecol. Oncol., 45 (3): 284-9 (1992); Bertelsen, K. et al., Gynecol. Oncol. 49 (1): 30-3691993); Lambert et al., Int. J. Gynecol. Cancer, 5(1): 41 (1995))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Treatment of patients with advanced ovarian cancer

[0025] Twenty-nine patients with suboptimally resected epithelial ovarian cancer who had been histologically determined to be FIGO stage IIIc or IV and who had achieved clinically definite completeness after six courses of platinum / paclitaxel-based chemotherapy were selected. answer. A clinically defined complete response was defined as no evidence of disease on physical examination and computed tomography testing, and CA-125 ≤ 35 units / mL. All patients had a physical status of 0-2 according to Zubrod's standard. The mean age of the patients was 57 (age range 46-79). At the time of initial cytoreductive surgery, 26 patients had FIGO stage IIIC tumors and 3 patients had stage IV tumors. All patients belonged to the case of suboptimal tumor resection. Eighteen patients had papillary serous histology, 6 patients had endometrioid histology, and 5 patients had mixed histology. The patient demographics are shown in Tab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for treating advanced epithelial ovarian cancer patients who attain a clinically-defined complete response after initial platinum / paclitaxel-based chemotherapy is described. The method involves administering a chemotherapeutic agent, such as doxorubicin, entrapped in liposomes.

Description

technical field [0001] The subject matter described herein relates to methods of treating advanced ovarian cancer in patients who have previously received platinum / paclitaxel-based chemotherapy. More specifically, the subject matter relates to methods of treating treatment-experienced patients with advanced ovarian cancer with doxorubicin encapsulated in liposomes. Background technique [0002] Ovarian cancer is the leading cause of death in patients with gynecological malignancies. The estimated number of cases and deaths in 2005 were 22,220 and 16,210, respectively (Jemal A., et al., CA Cancer J. Clin., 55(1):10-30(2005)). Most women diagnosed with advanced epithelial ovarian cancer show a clinically sound response to platinum / paclitaxel chemotherapy (Cannistra, S.A., N. Engl. J. Med., 351 (24): 2519-29 (2004)). Overall response rates can exceed 70%, with complete clinical response rates of approximately 30-50% for patients with suboptimally resected disease (McGuire, W...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K9/127A61P35/00
CPCA61K9/0019A61K31/704A61K9/1271A61P35/00A61K9/127
Inventor R·D·阿尔瓦雷斯M·J·小斯特劳恩
Owner ALZA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com